机构：[1]Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China,[2]Institute of Respiratory and Occupational Diseases, Collaborative Innovation Center for Cancer, Medical College, Shanxi Datong University, Datong, China,[3]School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China,[4]Infinitus (China) Company Ltd., Jiangmen, China
As a quinonemethide triterpenoid extracted from species of the Celastraceae and Hippocrateaceae, pristimerin has been shown potent anti-cancer effects. Specifically, it was found that pristimerin can affect many tumor-related processes, such as apoptosis, autophagy, migration and invasion, vasculogenesis, and drug resistance. Various molecular targets or signaling pathways are also involved, such as cyclins, reactive oxygen species (ROS), microRNA, nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK), and PI3K/AKT/mammalian target of rapamycin (mTOR) pathways. In this review, we will focus on the research about pristimerin-induced anti-cancer activities to achieve a deeper understanding of the targets and mechanisms, which offer evidences suggesting that pristimerin can be a potent anti-cancer drug.
基金：
The work was supported by National Natural Science Foundation
of China (81473320 and 81773888), Fund of Guangdong Science
and Technology Department (2016A020226024), Fund of
Guangzhou Science and Technology Program (201707010048),
Fund of Guangdong Education Department (2015KTSCX112),
and Fund of Construction of High Level Universities in
Guangdong (Nanshan Scholars Program and Academic
Backbone Program).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类|2 区医学
小类|2 区药学
最新[2025]版：
大类|3 区医学
小类|3 区药学
第一作者：
第一作者机构：[1]Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China,
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Jia-jun Li,Yan-yan Yan,Hong-mei Sun,et al.Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review.[J].Frontiers in pharmacology.2019,10:746.doi:10.3389/fphar.2019.00746.
APA：
Jia-jun Li,Yan-yan Yan,Hong-mei Sun,Yun Liu,Chao-yue Su...&Jian-ye Zhang.(2019).Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review..Frontiers in pharmacology,10,
MLA：
Jia-jun Li,et al."Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review.".Frontiers in pharmacology 10.(2019):746
